Clinical trials
Completed HIV Infections trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
119 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 6 |
| 2003 | 7 |
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 6 |
| 2011 | 9 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 119 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ViiV Healthcare | 29 |
| Boehringer Ingelheim | 18 |
| Gilead Sciences | 10 |
| Bristol-Myers Squibb | 6 |
| GlaxoSmithKline | 5 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Abbott | 4 |
| Tibotec Pharmaceuticals, Ireland | 4 |
| Bavarian Nordic | 3 |
| Hoffmann-La Roche | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| HIV Infections | 119 |
| Acquired Immunodeficiency Syndrome | 29 |
| Infections | 11 |
| AIDS-Related Opportunistic Infections | 2 |
| Hepatitis C | 2 |
| AIDS Dementia Complex | 1 |
| Candidiasis | 1 |
| Candidiasis, Oral | 1 |
| Coronary Disease | 1 |
| Cytomegalovirus Infections | 1 |
Trials
Showing 1 to 25 of 119. Each trial links to its page on Pharma Observatory.
19 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.